N., Kitz, K., Rossmann, C., Bernhart, E., Huber, E., Trummer, C., Windischhofer, W., Sattler, W., and Malle, E
Readers should confirm current details directly with WellMedr before enrolling
Another recent example of a class I c-MET inhibitor in earlier phases of clinical development is AMG - 337 (Amgen, Thousand Oaks, California, USA), an orally bioavailable highly selective inhibitor of the c-MET receptor with a half maximal inhibitory concentration (IC50) of 1 nM which has reached phase II studies in patients with GI cancer or other MET-amplified solid tumors [112]
Blend Structure Research Areas Cellular Energy & Mitochondrial Function Metabolic Regulation & Obesity Research Muscle Preservation & Physical Performance Neuroprotection & Cognitive Function Longevity & Anti-Aging Mechanisms Preclinical Cancer Research
Naringenina per sostenere il sistema immunitario